About Event
2nd ALS Drug Development Summit – What to Look Forward to in 2023!
With 3 days of jam-packed content and 35+ world class speakers pioneering the next wave of ALS therapies, the 2nd ALS Drug Development Summit is biopharma’s can’t-miss meeting for the acceleration of ALS drug development pipelines.
Join 100+ of your biopharma peers to uncover cutting-edge ALS biomarkers, including neurofilament light chain, to incorporate into clinical trials, improve in vitro and in vivo ALS preclinical models to improve translation of safe and efficacious therapies and optimize clinical trial design and endpoints to maximise data collection in an evolving standard of care.
Join Leading ALS Biopharma to Hear From:



Amylyx Pharmaceuticals on the journey to their recent FDA approval of Relyvrio to learn key takeaways interacting with regulatory bodies
Biogen on late-stage clinical findings of Toferson vs SOD1 to understand strategy approaching ALS endpoints
Eli Lilly to explore neurofilament light chain capabilities as a biomarker to measure therapeutic effect on ALS disease progression


Sanofi to spotlight the latest insights into overarching ALS pathophysiology to identify novel targets to benefit the wider patient population
Mitsubishi Tanabe Pharma and Massachusetts General Hospital on incorporating digital biomarkers and remote monitoring technology into decentralized clinical trials to ease the participant clinical research experience
Who Will You Meet?

The 2nd ALS Drug Development Summit will unite leading experts across all stages of the ALS drug development pipeline including, ALS biomarker pioneers, preclinical in vitro and in vivo model specialists, translational KOLs, ALS discovery and genetics scientists, clinical development leaders and neurodegenerative regulatory experts.

Uniting 100+ ALS experts from the likes of Biogen, Amylyx Pharmaceuticals, Eli Lilly, QurAlis, Sanofi, Brainstorm Cell Therapeutics, and many more, this is CNS biopharma’s must-attend meeting to overcome your translational challenges and provide efficacious therapeutics for the unmet need in ALS.